Member Description Overlay
Equity Research

The hallmark of SVB Leerink's market-leading equity research product is a commitment to creating deep, differentiated and proprietary knowledge.

The hallmark of SVB Leerink’s market-leading equity research product is a commitment to creating deep, differentiated and proprietary knowledge.

  • Our therapeutics, medical technology and life sciences analysts’ work is based in fundamental research of the molecular, cellular and pharmaceutical science that underlie new healthcare products.
  • Our information technology and services senior research analysts study healthcare’s regulatory, payor, technology and competitive environments. They project industry changes as a result of influences including the powerful cost and health outcome effects of emerging software products and strategies based in “Big Data.” Our analysts help investors understand what these shifts mean and the opportunity in emerging Digital Health capabilities for the healthcare and life science industry, its companies and financial results.
  • The advanced scientific and medical training as well as healthcare and life science industry experience of our analysts gives foundation and context to our work and recommendations, while access to SVB Leerink’s vast MEDACorp network of healthcare specialists enriches our knowledge and improves our research offering.

Our analysts provide research coverage on an extensive list of leading and emerging healthcare and life science companies:

Universe of Coverage by Company ¦ Universe of Coverage by Sector

John L. Sullivan, CFA

Senior Managing Director, Director of Equity Research & Healthcare Investment Strategist

close

John L. Sullivan, CFA

Senior Managing Director, Director of Equity Research & Healthcare Investment Strategist

John L. Sullivan is the Director of Equity Research & Healthcare Investment Strategist at SVB Leerink.

Prior to joining the firm in 2004, Mr. Sullivan was a Vice President, Senior Equity Research Analyst at Stephens Inc. where his primary focus was on companies possessing enabling technologies for health care-related products for research and drug discovery.

As a sector analyst, Mr. Sullivan ranked #3 in The Wall Street Journal’s 2008 “Best on the Street” analysts’ survey. As a stock picker in 2007, he earned a #2 ranking among the life sciences tools and services analysts ranked by StarMine in Forbes.com and a #3 ranking among the same group for accuracy of his earnings estimates.

Mr. Sullivan earned his undergraduate degree in Finance from Boston University, a graduate degree in Finance from Northwestern University’s Kellogg School of Management and a graduate degree in Government from Harvard University. Mr. Sullivan is a CFA charterholder.

Jim Kelly

Managing Director, Associate Director of Research

close

Jim Kelly

Managing Director, Associate Director of Research

Jim Kelly is a Managing Director, Associate Director of Equity Research at SVB Leerink. Mr. Kelly is responsible for product management, analyst development and equity strategy.

Prior to joining SVB Leerink in 2015, Mr. Kelly worked at Credit Suisse, where he served in research management as an Associate Director of Equity Research in New York and was responsible for leading key, strategic initiatives in research product and process development. Prior to his ADOR role at Credit Suisse, Mr. Kelly spent 13 years in Equity Research covering the US Pharmaceuticals industry for Lehman Brothers, Goldman Sachs and Credit Suisse First Boston.

Mr. Kelly received his MBA from Columbia Business School and earned his B.S. in Mechanical Engineering from Lehigh University.  Mr. Kelly also serves on the board of the Lehigh Business School Dean’s Advisory Council.